• 尊龙凯时人生就是搏·(中国区)官方网站

    Apeloa
    尊龙人生就是搏中国区药业
    DS Technology Platforms
    Flow Chemistry Synthetic Biology & Biocatalysis Highly Potent Compound Peptide TPD/PROTAC Oligonucleotide Synthesis Crystallization & Particle Engineering Preparation & Separation
    TPD/PROTAC Platform
    Apeloa TPD/PROTAC Platform offers comprehensive services for the development of targeted protein degradation therapeutics, including PROteolysis Trgeting Chimeras (PROTACs). With over 80 PROTAC-focused scientists and two dynamic chemistry service teams located in Boston and Hengdian, the platform provides expertise throughout the entire PROTAC development process. From target validation, hit generation, lead optimization, to clinical development, Apeloa leverages its integrated parallel synthesis platform, extensive E3 ligand, linker, and POI binder intermediate libraries, and strong analytical and ADME capabilities to drive PROTAC projects forward efficiently.
    尊龙人生就是搏中国区药业
    Team
    Apeloa TPD/PROTAC Platform is led by a team of highly experienced scientists, including co-inventors of two approved NDAs and one Phase II IND. The team comprises 12 Ph.D. holders with a combined synthetic chemistry experience of over 100 years, and a tot
    Services
    ● Design, synthesis, and optimization of PROTAC molecules ● Synthesis and optimization of E3 ligands, linkers, and POI binders ● Rapid construction of early screening intermediate libraries via parallel synthesis platform ● Analytical, purification, and ADME evaluation studies ● Non-GMP and GMP scale-up production services
    Equipment
    ●400Hz/600Hz NMR (Bruker/Avance) ●LC-Q-TOF (Agilent) ●LC-MSMS (Shimadzu/Waters/Agilent) ●GC-MSMS (Agilent/Shimadzu) ●HPLC (Waters) ●XRD (Rigaku) ●ICP-MS (Perkin Elmer)
    Advantages 1
    Advantages 2
    Advantages 3
    Advantages 4
    Advantages 5
    尊龙人生就是搏中国区药业
    Extensive Intermediate Library
    ● Over 300 E3 ligands and ligand-linker conjugates in stock ● Expedites PROTAC synthesis and screening
    尊龙人生就是搏中国区药业
    Flexible E3 Ligand and Linker Combinations
    ● Facilitates optimization of degradation efficiency and physiochemical properties
    尊龙人生就是搏中国区药业
    Efficient Parallel Synthesis Platform
    Rapid construction of intermediate libraries for early screening
    尊龙人生就是搏中国区药业
    Expertise in E3 Ligand Scale-up
    ● Optimized synthetic routes for key clinical PROTAC ligands (e.g., Kymera CRBN, ARV-471, ARV-110) ● Improved yields, reduced costs, and addressed challenges like epimerization
    尊龙人生就是搏中国区药业
    Retrosynthetic Approach for PROTAC Synthesis
    ● Avoids epimerization and purification challenges ● Utilizes easy-to-purify fragments and conjugate intermediates